TCR2 Therapeutics Inc. announced the appointment of Rosemary Harrison, Ph.D., as Chief Business and Strategy Officer where she will be responsible for supporting a range of activities including commercial strategy, operational planning, corporate partnerships and long-term growth opportunities. Dr. Harrison brings to TCR2 nearly 20 years of global experience working on strategic planning, portfolio management, and business development at both pharmaceutical and biotechnology companies. Prior to joining the Company, she was Senior Vice President of Corporate Development and Strategy at Trillium Therapeutics where she led its acquisition by Pfizer for $2.22 billion in November 2021.